Non-Small Cell Lung Cancer- Localized and Unresectable

CROSS-DISEASE TRIALS:

IRB#19537
Pacific-4:
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4)

IRB#22221
S1933:
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

IRB#22221
S1933:
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

Correlatives

No Trials Currently Available

Inoperable Stage I/II

Inoperable Stage IIIA/B

KEY
Open to Enrollment
In Development
Enrollment on Hold

24 JAN 2022
https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result